board of directors

Bob More
Chairman of the Board; Managing Director, Alta Partners

Bob More is currently Managing Director at Alta Partners. Prior to Alta, Bob was at the Bill and Melinda Gates Foundation where he served as a Senior Advisor working on Program Related Investments and leading the foundation’s Global Health Venture Capital initiative. Previously, Bob was a Partner at Frazier Healthcare from 2008-2013 and a Partner at Domain Associates, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000. From 1997-1998, Bob served as the Chief Operating Officer of Small Molecule Therapeutics. Prior to attending business school, Bob held a Sales Position with Pharmacia and began his career in research at Somatogen, a start-up focused on a recombinant blood substitute. As a venture capitalist, Bob lead and oversaw investments in Biotechnology, Pharmaceuticals, Medical Devices and Health Care IT. Bob was a Founding Board Member of the Kauffman Fellows Program and serves on several outside boards. He also serves as Chairman of One Revolution, an organization focused on challenging perspectives on disabilities. Bob received his BA from Middlebury College and an MBA from the Darden School of Business Administration at the University of Virginia.

Steven Altschuler, MD
Managing Director, Ziff Capital Healthcare Ventures

Steven Altschuler brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners. In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts towards investing in, and facilitating the startup and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is a member of the board of directors of WW (formerly Weight Watchers International), Orchard Therapeutics, 89Bio, AsclepiX Therapeutics, ImVaX, and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham. Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.

Steven Brugger
President and CEO, Affinivax

Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.

Andrew Hack, MD, PhD
Managing Director, Bain Capital Life Sciences

Andrew Hack is a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Before joining Bain Capital, Dr. Hack was the Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) from July 2015 through March 2019. Previously, Dr. Hack served as a portfolio manager at Millennium Management, where he ran a healthcare hedge fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Dr. Hack was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career as an equity research analyst covering the biotechnology sector at Banc of America Securities after serving as Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company. In addition, Dr. Hack is a member of the Board of Directors of Allena Pharmaceuticals (Nasdaq: ALNA), Atea Pharmaceuticals (Nasdaq: AVIR), BCLS Acquisition Corp (Nasdaq: BLSA), Dynavax Technologies (Nasdaq: DVAX), Imperative Care, JenaValve Technology, and Mersana Therapeutics (Nasdaq: MRSN). Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.

Frances Heller
Founder, CEO & Board of Directors, Good2Go, Inc.

Fran Heller has over 25 years of experience in the pharmaceutical and biotech industries in business development, licensing and legal affairs. Currently, Ms. Heller is the Founder, CEO and Chair of Good2Go, Inc. an IoT technology company. She also co-chairs the LavaMaeˣ board, a nonprofit that promotes well-being to people experiencing homelessness. Previously she was senior vice president of business development at Bristol-Myers Squibb, a Trustee of the Bristol-Myers Squibb Foundation, a Trustee at Dana Farber Cancer Institute, and an adviser to GoFundMe’s Impact Fund. Ms. Heller is a member of the California State Bar and licensed by the U.S. Patent and Trademark Office. She holds a B.S. in biology from Tulane University, an M.A. in biology from American University and a J.D. from Golden Gate University School of Law.

Kris Jenner, MD, DPhil
Co-founder and Managing Member of Rock Springs Capital

Kris Jenner, M.D., D. Phil., is a co-founder and Managing Member of Rock Springs Capital.  Rock Springs is a healthcare dedicated investment fund that was founded in 2013 and invests in equities across subsectors including pharmaceuticals, biotech, medical devices and healthcare services.  Prior to founding Rock Springs Capital, Dr. Jenner was a vice president of T. Rowe Price Group, Inc., where he was a portfolio manager and research analyst in the U.S. Equity Division specializing in the coverage of U.S. pharmaceutical and biotechnology companies. He was the portfolio manager of the Health Sciences Fund from 2000 until his departure in February 2013.  Prior to joining T. Rowe Price in 1997, he worked at the Laboratory of Biological Cancer, The Brigham & Women’s Hospital, Harvard Medical School. He earned a B.S. in chemistry, summa cum laude, from the University of Illinois, a D. Phil. from Oxford University, and an M.D. from the Johns Hopkins University, School of Medicine. Dr. Jenner completed two years of a general surgery residency at the Johns Hopkins Hospital.

Richard Malley, MD
Kenneth McIntosh Chair in Pediatric Infectious Diseases, Boston Children’s Hospital and Harvard Medical School; Affinivax scientific founder

Richard Malley is Affinivax’s scientific founder and the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital. He is also the Director of the Travel and Geographic Medicine Clinic at Boston Children’s Hospital. He runs an NIH-funded laboratory where his group focuses on various aspects of bacterial pathogenesis, natural- and vaccine-induced immunity and the development of novel vaccine technologies, such as the Multiple Antigen Presenting System (MAPS). As an experienced physician with more than 20 years of experience treating infectious diseases, Dr. Malley has led an international effort in the development of novel vaccines in collaboration with colleagues and global nonprofit health organizations such as PATH and the Bill and Melinda Gates Foundation.

David Rossow
Founding Partner, Strategic Investment Fund, the Bill & Melinda Gates Foundation

David Rossow is a Board Observer and a Founding Partner of the Strategic Investment Fund at the Bill & Melinda Gates Foundation overseeing program-related investments in global health, global development, global growth and opportunity, and US programs from the foundation’s $2.0 billion allocation. He currently heads the fund’s international work with a focus on biotech in Europe and Israel, and tech-enabled service/product delivery in South Asia and Sub-Saharan Africa. Prior to joining the foundation in 2010, David worked on deal teams in private equity and investment banking, where he was responsible for executing leveraged buyout, equity, debt, restructuring, and merger & acquisition transactions across a variety of industries.

George Siber, MD
Former Executive Vice President and Chief Scientific Officer of Wyeth Vaccines

George Siber has served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines, or Wyeth. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar, a pneumococcal vaccine which has achieved multibillion dollar revenues; Acel-Imune, an acellular pertussis vaccine; and Meningitec, a meningococcal meningitis vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. Dr. Siber holds an MD degree from McGill University in Canada, received post-doctoral training in Internal Medicine at Rush-Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and Infectious Disease and vaccinology training at Children’s Hospital and Beth Israel Hospital, Harvard Medical School Boston.

Back to Top
 

This links to an external website.

Continue